(Most of the reform was ultimately abandoned after a series of successful court challenges, of which Novo Nordisk Canada was a party.) Thomas Digby, a B.C.-based intellectual-property lawyer and chair of the review board from 2023 to 2025, said that if its true that Novo abandoned its Ozempic/Wegovy patent in order to avoid PMPRB review, choosing instead to face generic entry, then its completely unprecedented in my experience, and quite possibly a strategic business mistake. Patent protections will lapse in India and Brazil in March, and in China and Turkey later in the year
The results can differ, but many notice better stamina and less hunger almost right away
(2023) 4:e363
Glutathione programs are uniquely exposed to oxidation-grade variability and phospholipid supply quality
A 2025 review in Cell highlighted the benefit of GLP-1 therapies on anti-inflammatory mechanisms involved in cardiovascular, kidney and liver conditions, and disorders like obstructive sleep apnea
When combined with glucose (blood sugar), [dA(2)]GLP-1/GcG dramatically boosted the blood levels of insulin and decreased blood sugar levels in normal and obese diabetic mice